Skip to main content

Research Repository

Advanced Search

All Outputs (72)

Enhanced nanoparticle uptake into virus infected cells: could nanoparticles be useful in antiviral therapy? (2018)
Journal Article

Virus infections cause diseases of different severity ranged from mild infection e.g. common cold into life threatening diseases e.g. Human Immunodeficiency virus (HIV), Hepatitis B. Virus infections represent 44% of newly emerging infections. Althou... Read More about Enhanced nanoparticle uptake into virus infected cells: could nanoparticles be useful in antiviral therapy?.

Synthesis of nucleoside-boronic esters hydrophobic pro-drugs: a possible route to improve hydrophilic nucleoside drug loading into polymer nanoparticles (2018)
Journal Article

Nucleoside analogues are active therapeutic agents for different types of diseases e.g. Cancer and virus infections. However, they are associated with several side effects due to off-target accumulation. Particulate delivery systems such as nanoparti... Read More about Synthesis of nucleoside-boronic esters hydrophobic pro-drugs: a possible route to improve hydrophilic nucleoside drug loading into polymer nanoparticles.

Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus (2018)
Journal Article

Objective: Recently approved direct acting antivirals provide transformative therapies for chronic hepatitis C virus (HCV) infection. The major clinical challenge remains to identify the undiagnosed patients worldwide, many of whom live in low-income... Read More about Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus.

Host genetic factors associated with hepatocellular carcinoma in patients with hepatitis C virus infection: a systematic review (2018)
Journal Article

Hepatitis C virus (HCV)-infected patients are at risk of developing hepatocellular carcinoma (HCC). Individuals at heightened riskcould be targeted by intensive follow-up surveillance. We have conducted a systematic review of the literature to identi... Read More about Host genetic factors associated with hepatocellular carcinoma in patients with hepatitis C virus infection: a systematic review.

Establishing the cascade of care for hepatitis C in England-benchmarking to monitor impact of direct acting antivirals (2017)
Journal Article

Little is known about engagement and retention in care of people diagnosed with chronic hepatitis C (HCV) in England. Establishing a cascade of care informs targeted interventions for improving case-finding, referral, treatment uptake and retention i... Read More about Establishing the cascade of care for hepatitis C in England-benchmarking to monitor impact of direct acting antivirals.

SOX9 predicts progression towards cirrhosis in patients while its loss protects against liver fibrosis (2017)
Journal Article

Fibrosis and organ failure is a common endpoint for many chronic liver diseases. Much is known about the upstream inflammatory mechanisms provoking fibrosis and downstream potential for tissue remodeling. However, less is known about the transcriptio... Read More about SOX9 predicts progression towards cirrhosis in patients while its loss protects against liver fibrosis.

MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C (2016)
Journal Article

© 2016 The Author(s). Cirrhosis likely shares common pathophysiological pathways despite arising from a variety of liver diseases. A recent GWAS identified rs641738, a polymorphism in the MBOAT7 locus, as being associated with the development of alco... Read More about MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C.

Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis (2016)
Journal Article

Direct-acting antivirals have become widely used for patients with chronic hepatitis C virus infection with decompensated cirrhosis. Virological responses are excellent and early improvements in liver function, at least in a proportion of patients, h... Read More about Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis.

Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis (2016)
Journal Article

© 2016 European Association for the Study of the Liver. Background & Aims All oral direct acting antivirals (DAAs) effectively treat chronic hepatitis C virus (HCV) infection, but the benefits in advanced liver disease are unclear. We compared outcom... Read More about Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.

Clinical care pathways for patients with hepatitis C: reducing critical barriers to effective treatment. (2016)
Journal Article

Background: Engagement of individuals infected with hepatitis C virus (HCV) with care pathways remains a major barrier to realizing the benefits of new and more effective antiviral therapies. After an exploratory study, we have undertaken an evidence... Read More about Clinical care pathways for patients with hepatitis C: reducing critical barriers to effective treatment..

A diverse panel of hepatitis C virus glycoproteins for use in vaccine research reveals extremes of monoclonal antibody neutralization resistance (2015)
Journal Article

Despite significant advances in the treatment of hepatitis C virus (HCV) infection, the need to develop preventative vaccines remains. Identification of the best vaccine candidates and evaluation of their performance in preclinical and clinical devel... Read More about A diverse panel of hepatitis C virus glycoproteins for use in vaccine research reveals extremes of monoclonal antibody neutralization resistance.